A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors.

For the third quarter, Pfizer reported overall revenue ... it aims to get FDA approval for 10 products like cancer treatments ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of ...

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...

The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...

Also Read: DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals ... Novavax is scheduled to release its third-quarter earnings tomorrow, Tuesday.

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective dropped by research analysts at Barclays from $125.00 to $111 ...

reported its third-quarter earnings. Even though the company surprised analysts by reporting net income of $13 million (up ...